Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

P Langton, G Hankey, J Eikelboom

    Research output: Contribution to journalLetter

    Original languageEnglish
    Pages (from-to)199-199
    Number of pages1
    JournalMedical Journal of Australia
    Volume182
    Issue number4
    Publication statusPublished - 21 Feb 2005

    Cite this

    @article{9f07b00335074b1fb0d330d996f909ae,
    title = "Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions",
    keywords = "RANDOMIZED CONTROLLED-TRIALS, ENDOTHELIAL FUNCTION, OSTEOARTHRITIS, INHIBITION, VALDECOXIB, EFFICACY, DISEASE",
    author = "P Langton and G Hankey and J Eikelboom",
    year = "2005",
    month = "2",
    day = "21",
    language = "English",
    volume = "182",
    pages = "199--199",
    journal = "Medical Journal Australia",
    issn = "0025-729X",
    publisher = "Australasian Medical Publishing Co. Ltd",
    number = "4",

    }

    Cardiovascular safety of rofecoxib (Vioxx) : lessons learned and unanswered questions. / Langton, P; Hankey, G; Eikelboom, J.

    In: Medical Journal of Australia, Vol. 182, No. 4, 21.02.2005, p. 199-199.

    Research output: Contribution to journalLetter

    TY - JOUR

    T1 - Cardiovascular safety of rofecoxib (Vioxx)

    T2 - lessons learned and unanswered questions

    AU - Langton, P

    AU - Hankey, G

    AU - Eikelboom, J

    PY - 2005/2/21

    Y1 - 2005/2/21

    KW - RANDOMIZED CONTROLLED-TRIALS

    KW - ENDOTHELIAL FUNCTION

    KW - OSTEOARTHRITIS

    KW - INHIBITION

    KW - VALDECOXIB

    KW - EFFICACY

    KW - DISEASE

    M3 - Letter

    VL - 182

    SP - 199

    EP - 199

    JO - Medical Journal Australia

    JF - Medical Journal Australia

    SN - 0025-729X

    IS - 4

    ER -